After a prolonged period of tight labor market conditions, new data from ANZ Banking Group $ANZ.AX and employment platform Indeed indicate a potential shift in Australia’s employment dynamics. Job advertisements in May 2025 declined for the second consecutive month, falling by 1.2% following a 0.3% drop in April. Although demand for labor remains elevated compared to pre-pandemic levels, this downward trend suggests a gradual normalization in hiring momentum.

Sanofi and Regeneron Pharmaceuticals faced notable share price declines after mixed results from late-stage clinical trials of their experimental drug, itepekimab, targeting chronic obstructive pulmonary disease (COPD) in former smokers. On Friday, Sanofi disclosed that its phase III trials produced diverging efficacy data. In one study, the drug demonstrated a 27% reduction in the rate of COPD exacerbations, suggesting meaningful therapeutic potential. However, parallel research failed to replicate these benefits, despite earlier, more positive interim outcomes.

Ola Electric Mobility Ltd. $OLAELEC.NS recorded its sharpest intraday selloff since April 7, as quarterly results highlighted deepening losses and a sharp revenue contraction. The company reported a net loss of 8.7 billion INR (approximately 102 million USD) for the quarter ending March 31. This figure represents more than a twofold increase compared to last year's 4.16 billion INR loss. Concurrently, revenue dropped 62% year-on-year to 6.11 billion INR, indicating persistent headwinds in market demand and operational efficiency.